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Volume 58, Number 4 Abstracts 1141was associated with re-establishment of the endothelial lining, suspension of
proteolysis, and reconstitution of a new aortic wall with smooth muscle cells
and extra cellular matrix. ECs exerted their healing properties through para-
crine mechanisms involving up-regulation of endothelium-derived stabi-
lizing factors and recruitment of resident vascular cells. They did not
appear to directly participate in aortic wall repair. Transplantation of
outgrowth ECs (n ¼ seven) reduced by 30% progression of AAAs and
restored abluminal endothelium at 28 days compared with controls (n ¼
nine).
Comment: The authors demonstrate that it is possible using EC seed-
ing techniques to institute recovery of the luminal endothelial lining in an
animal model of AAA. In addition, this new endothelial lining through para-
crine effects appears to result in stabilization of the AAA. It has been previ-
ously known that re-endothelialization of denuded arteries can modulate
the vascular smooth muscle cell phenotype in neointimal hyperplasia. This
study, however, is the ﬁrst to extend this concept to stabilization of
AAAs. It is a unique contribution and perhaps sheds new light on AAA path-
ophysiology and, from the clinical perspective, suggests ultimately a new
mechanism of potentially arresting the growth of AAAs.
Economic Analysis of a Randomized Trial of Percutaneous
Angioplasty, Supervised Exercise or Combined Treatment for
Intermittent Claudication due to Femoropopliteal Arterial Disease
Mazari FAK., Kahn JA., Carradice D., et al. Br J Surg 2013;100:1172-9.
Conclusion: Supervised exercise therapy (SET) is the most cost-effec-
tive ﬁrst-line treatment for intermittent claudication. SET in combination
with percutaneous angioplasty (PTA) is also more cost-effective than PTA
alone.
Summary: This study reports the economic analysis of the authors’
previous study comparing PTA, SET, and combined treatment for intermit-
tent claudication (IC) due to femoropopliteal disease (Mazari FA et al, Br J
Surg 2012;99:39-48). In the original trial, patients with IC secondary to
femoropopliteal disease were randomized to receive PTA, SET, or the
combination of PTA plus SET. Clinical and quality of life indicators were
recorded before therapy and at 1, 3, 6, and 12 months after intervention.
The Short Form-6D health utilities index was calculated from the Short-
Form 36 and plotted. Quality-adjusted life-years (QALYs) were generated
through calculations of the area under the curve. Costs were calculated
using the British National Health Service 2009 to 2010 payment-by-results
tariffs and the National Institute for Health Research Clinical Research
Network Investigation pricing index and adjusted for reinterventions.
Cost per QALY and incremental costs were calculated. A sensitivity analyses
was also performed. A total of 178 patients were randomized (PTA, 60;
SET, 60; PTA+SET, 58). In all treatment groups, there was signiﬁcant
improvement in the SF-6D index (P < .001). There was, however, no
signiﬁcant difference between treatments in mean (95% conﬁdence interval)
QALYs gained (PTA: 0.620 [0.588-0.652]; SET: 0.627 [0.597-0.660];
PTA+SEP: 0.649 [0.622-0.675]). The adjusted mean cost per procedure
was signiﬁcantly higher for PTA (€7301.74) than for SET (€3866.49) and
PTA+SET (€6911.68; P < .001). Costs per QALY were higher for PTA
(€11777.00) compared with SET (€6147.04) and PTA+SET (€10649.74).
This was due to the PTA-alone group undergoing more reinterventions
than the PTA+SET group (nine vs zero reinterventions). QALYs were
lost when PTA alone was used as ﬁrst-line treatment compared with SEP
or PTA+SET. Results were robust and valid in sensitivity analyses.
Comment: On the basis of this analysis, one has to wonder why payers
are willing to pay for percutaneous procedures for treatment of IC but are not
willing to pay for SET for treatment of IC? If one is going to pay for percu-
taneous procedures for treatment of IC, it would seem reasonable to require
that patients treated with percutaneous procedures for IC also be enrolled in
a SET program and that the SET program be paid for as well. The data here
suggest that if one is willing to pay for percutaneous procedures for IC,
requiring SET will actually result in overall decreased costs.
Homocysteine Improves Risk Stratiﬁcation in Patients Undergoing
Endarterectomy for Asymptomatic Internal Carotid Artery Stenosis
Duschek N., Ghai S., Sejkic F., et al. Stroke 2013;44:2311-4.
Conclusion: High plasma homocysteine (Hcy) levels suggest older
patients with asymptomatic carotid stenosis might beneﬁt from intensive
medical therapy rather than from carotid endarterectomy (CEA).
Summary: CEA for asymptomatic patients with high-grade carotid
stenosis (ACAS) has become very controversial. Medical therapy has
advanced, and beneﬁt from CEA for ACAS may be reduced and, some
contend, perhaps eliminated (Abbott AL, Stroke 2009;40:e573-83; and
Spence JD et al, Arch Neurol 2010;67:180-6). The authors of this article
point out that myocardial infarction is responsible for up to 50% ofperioperative deaths after CEA and causes more postoperative deaths than
stroke (Hertzer NR, Arison R. J Vasc Surg 1985;2:661-8). Therefore,
potential candidates for risk stratiﬁcation for carotid surgery include those
with cardiovascular morbidity. A potential candidate for risk stratiﬁcation
is the amino acid Hcy, which is acknowledged as a risk factor for cardiovas-
cular adverse events. In this study, the authors assessed plasma levels of total
Hcy (tHcy) as a biomarker to predict postoperative survival in patients with
ACAS. The study was a prospective, nonrandomized, case series from 2003
to 2012 in which 214 consecutive patients, 130 aged <75 years and 84 aged
$75 years, who underwent CEA for asymptomatic internal carotid artery
stenosis were observed for 8.5 years for occurrence of death after CEA as
the primary end point. Major cardiovascular risk factors and tHcy were
used for computation of prognostic indices. Kaplan-Meier curves were
used to estimate cumulative survival of prognostic indices-based quintiles.
tHcy had a signiﬁcant effect on postoperative survival (P < .0001). tHcy-
based quintiles of prognostic indices showed a better prediction of survival
than age alone. The result was reclassiﬁcation of 17 patients (20.2%) aged
>75 years as ﬁt for surgery but also indicated a high risk for 19 patients
(14.6%) aged <75 years. CEA could not be advised in 79.8% of patients
aged >75 years because of a signiﬁcantly reduced 5-year survival rate.
Comment: In essence, the authors’ data suggest best medical treat-
ment that includes B-vitamins, taking into account folate status, vitamin
B12 status, and renal function, may be a preferred path over CEA in older
hyperhomocysteinemic patients with ACAS. The data, however, lack
a control group of patients with high-grade ACAS who did not undergo
CEA and in whom adverse events were correlated to tHcy levels. As such,
Hcy levels alone are not likely to emerge, based on this study, as a primary
determinant of eligibility for CEA for ACAS. However, the concept that
modifying overall cardiovascular risks in patients with ACAS should be
a concern equal to or greater than neurologic outcome in this patient group
seems quite reasonable.
Blood Pressure and Cholesterol Control in Hypertensive
Hypercholesterolemic Patients: National Health and Nutrition
Examination Surveys 1988-2010
Egan BM., Li J., Qanungo S., et al. Circulation 2013;128:29-41.
Conclusion: There has been signiﬁcant progress in concomitant
hypertension and hypercholesterolemia control. However, signiﬁcant op-
portunities for improvement still remain.
Summary: Most hypertensive patients are also afﬂicted with hypercho-
lesterolemia. In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT),
lowering low-density lipoprotein cholesterol (LDL-C) from 133 mg/dL at
baseline to 87 mg/dL in hypertensive patients reduced coronary heart
disease 36% compared with placebo-treated patients (Sever PS et al, Lancet
2003;361:1149-58). In the Air Force/Texas Coronary Atherosclerosis
Prevention Study, treatment with lovastatin (20-40 mg/d), compared
with placebo, reduced LDL-C from 156 to 115 mg/dL and reduced coro-
nary heart disease 38% in hypertensive patients (Downs JR, et al, JAMA
1998; 279:1615-22). The National Health and Nutrition Examination
Surveys (NHANES) are used to address compliance issues relevant to control
of cardiovascular disease. In this study, the authors examined concurrent
hypertension and cholesterol control in the NHANES surveys from 1988
to 2010. Speciﬁcally, surveys from 1988 to 1994, 1999 to 2004, and
2005 to 2010 were analyzed. Hypertension was deﬁned by a blood pressure
$140/$90 mm Hg, current medication treatment, and twice-told hyper-
tension status; blood pressure <140/<90 deﬁned control. Hypercholester-
olemia was deﬁned by Adult Treatment Panel (ATP) III criteria based on 10-
year coronary heart disease risk, LDL-C levels, and non-high-density lipo-
protein cholesterol (HDL-C) levels, with values below diagnostic thresholds
deﬁning control. Across surveys, 60.7% to 64.3% of hypertensive patients
were also hypercholesterolemic. From 1988 to 1994 and 2005 to 2010,
control of LDL-C rose 9.2% to 45.4%. Control of concomitant hypertension
and LDL-C rose 5% to 30.7%, and control of combined hypertension and
non-HDL-C cholesterol rose 1.8% to 26.9%. The factors associated with
concomitant hypertension, LDL-C, and non-HDL-C control were statin
use (odds ratio [OR], 10.7), antihypertensive medications (OR, 3.32), age
per 10-year increase (OR, 0.77), two or more health care visits per year
(OR, 1.90), black race (OR, 0.59), Hispanic ethnicity (OR 0.62), cardiovas-
cular disease (OR, 0.44), and diabetes mellitus (OR, 0.54).
Comment: In essence, the data indicate use of statins and hyperten-
sive medications improve blood pressure and cholesterol control in hyper-
tensive hypercholesterolemic patients. This seems obvious, but perhaps
not so obvious is that the percentage of this population achieving control
is increasing over time. What also is not so obvious is that to achieve better
cardiovascular disease control in the United States population, targeting
patients with combined hypertension and hypercholesterolemia who are
also elderly, minorities, or who have diabetes perhaps may be facilitated
